CISH and colorectal cancer: In pre-clinical studies, inhibition of other immune checkpoints TGFβ and CIS (an NK cell IL-15 signalling checkpoint encoded by CISH) simultaneously results in enhanced NK cell activation and decreased MC38 colorectal cancer tumor burden in mice (407).